Nimetazepam is a nitrazepam that is substituted at positions 1 by a methyl group. It is used as an anticonvulsant and as a hypnotic for the short-term management of insomnia. Among its listed roles, it functions as a anticonvulsant, a sedative, a GABA modulator and an antispasmodic drug. It is a 1,4-benzodiazepinone and a C-nitro compound. Functionally, it is related to nitrazepam. Nimetazepam is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance. Nimetazepam (marketed under brand name Erimin) is an intermediate-acting hypnotic drug that is a benzodiazepine derivative. It was first synthesized by a team at Hoffmann-La Roche in 1962. It is grouped under the following drug class(es): Benzodiazepines and Schedule IV controlled substances. Its therapeutic use is listed as sleeping drugs. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include 1-Methylnitrazepam, Erimin and Methylnitrazepam. It is listed as a controlled drug substance (Schedule IV). Its PubChem CID is 4496.
Nimetazepam
| CAS No | 2011-67-8 |
|---|---|
| Molecular Formula | C16H13N3O3 |
| Molecular Weight | 295.29 g/mol |
| Synonyms | 1-methyl-7-nitro-5-phenyl-3H-1,4-benzodiazepin-2-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Nimetazepam is a nitrazepam that is substituted at positions 1 by a methyl group. It is used as an anticonvulsant and as a hypnotic for the short-term management of insomnia.
The listed CAS number is 2011-67-8.
The listed molecular formula is C16H13N3O3.
The listed molecular weight is 295.29 g/mol.
1-methyl-7-nitro-5-phenyl-3H-1,4-benzodiazepin-2-one.
The source lists 1-Methylnitrazepam, Erimin and Methylnitrazepam.